Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2025-04-01
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Magnetic Resonance Imaging to Identify Characteristics of Plaque Build-Up in People With Peripheral Arterial Disease
NCT00520312
Images in Extracranial Artery Stenosis
NCT00173927
Carotid Intima-media Thickness (IMT) and Large-vessel Atherosclerosis by Multidetector Computed Tomography (MDCT)
NCT00949169
Imaging of Plaque With Magnetic Resonance Imaging (MRI)
NCT00115856
Comprehensive Magnetic Resonance of Peripheral Arterial Disease
NCT00587678
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Objectives Primary Objective: To integrate multi-modal imaging data (NIR-II Imaging, DUS-based V-flow Imaging, and Laser Speckle Imaging) with multi-omics data using machine learning algorithms for improved disease prediction and stratification.
Study Design
This is a prospective, observational study involving patients diagnosed with PAD or CAS. The study will include the following components:
Imaging Analysis:
1. NIR-II Imaging: To visualize deep tissue vascular structures and hemodynamics.
2. DUS-based V-flow Imaging: To assess blood flow dynamics and vascular stenosis.
3. Laser Speckle Imaging: To evaluate microvascular perfusion and endothelial function.
Multi-Omics Analysis:
1. Single-cell Transcriptomics: To profile gene expression at the single-cell level and identify cell-type-specific changes.
2. Metabolomics and Lipidomics: To characterize metabolic and lipid profiles associated with disease progression.
3. Proteomics: To identify differentially expressed proteins and signaling pathways.
4. Data Integration and Machine Learning:
Imaging and multi-omics data will be integrated using advanced machine learning algorithms to develop predictive models for disease diagnosis, progression, and therapeutic response.
Study Population The study will enroll patients diagnosed with PAD or CAS, along with age- and sex-matched healthy controls. Inclusion and exclusion criteria will be applied to ensure a homogeneous study population.
Expected Outcomes
1. Identification of key molecular and cellular pathways involved in PAD and CAS pathogenesis.
2. Development of a multi-modal predictive model for accurate disease diagnosis and stratification.
3. Discovery of novel biomarkers and therapeutic targets for personalized medicine.
Ethical Considerations The study protocol has been reviewed and approved by the Institutional Review Board (IRB) to ensure the protection of human subjects. Informed consent will be obtained from all participants prior to their enrollment in the study.
Significance This study represents a pioneering effort to integrate multi-omics and multi-modal imaging data for a comprehensive understanding of PAD and CAS. The findings are expected to advance the field of vascular biology and contribute to the development of precision medicine approaches for these debilitating diseases.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Males or females aged between 18 and 85 years.
3. Diagnosed with Peripheral Artery Disease (PAD) or Carotid Artery Stenosis (CAS).
4. Participants are conscious, fully informed about the study content, and have signed the informed consent form, agreeing to participate in this study.
Exclusion Criteria
2. PAD patients who have previously undergone interventional treatments (e.g., balloon angioplasty or stent placement) and/or surgical procedures.
3. Patients with heart failure classified as NYHA Class II-IV or those with a history of coronary artery disease.
4. Patients with acute infections, tumors, severe arrhythmias, psychiatric disorders, or drug/alcohol addiction.
5. Significant liver dysfunction or a history of liver diseases, including: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding twice the upper limit of normal. History of cirrhosis, hepatic encephalopathy, esophageal varices, or portosystemic shunt.
6. Significant renal dysfunction or a history of kidney diseases, including: Serum creatinine levels exceeding 1.5 times the upper limit of normal. History of dialysis or nephrotic syndrome.
7. Pregnant women, those planning to become pregnant, or breastfeeding women.
8. Participation in other clinical trials within the past 3 months.
9. Refusal to sign the informed consent form or participate in this study.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yijie Ning
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yijie Ning
Doctor of vascular surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Honglin Dong
Role: PRINCIPAL_INVESTIGATOR
Second Hospital of Shanxi Medical University
Ruijing Zhang
Role: STUDY_DIRECTOR
Second Hospital of Shanxi Medical University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Ning Y, Hu J, Zhu Y, Tang W, Yan S, Li H, Zhang Z, Lu C, Ren K, Shi P, Yao T, Wang Q, Zhao Y, Gao T, Zhang R, Dong H. NIR-II imaging-based detection of early changes in lower limb perfusion in type 2 diabetes patients without peripheral artery disease. Diabetes Res Clin Pract. 2025 Mar;221:112038. doi: 10.1016/j.diabres.2025.112038. Epub 2025 Feb 8.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
[2025]YX024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.